Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer

BMC Cancer

Hu Chen²  Li Liao²  Jinchao Zhang¹  Qiong Wu¹  Guoliang Ding¹  Haiyan Gao²  Bin Zhang²  Danhong Wang² 

[1]Cell and Gene Therapy Center, Academy of Military Medical Sciences, Beijing, China

[2]Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China

关键词: Advanced renal cancer;    Cytokine-Induced Killer cell;    Dendritic cells;    Clinical research;   

Others  :  858906
DOI  :  10.1186/1471-2407-14-251

 received in 2013-09-05, accepted in 2014-04-03,  发布年份 2014

【 摘 要 】

Background

Renal cell carcinoma (RCC) is a malignant disease that demonstrates resistance to standard chemotherapeutic agents. Yet Active immunization using genetically modified dendritic cells holds promise for the adjuvant treatment of malignancies to eradicate or control residual disease. Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8⁺ T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities against tumor cells. Clinical studies have confirmed benefit and safety of CIK cell-based therapy for patients with malignancies. This clinical trial was conducted to evaluate efficacy and safety of genetically modified dendritic cells in combination with Cytokine-Induced Killer Cell (gmDCs-CIK) treatment of patients with RCC.

Methods

28 patients with advanced renal cancer were admitted to Affiliated Hospital of Academy of Military Medical Sciences from December 2010 to March 2012 and treated by gmDCs-CIK. Clinical efficacy and safety between pre- and post-treatment were compared.

Results

This analysis showed an objective response rate (ORR) of 39% and a disease control rate (DCR) of as 75%. There is no significant relationship between clinical efficacy and whether metastasis occurred or not (P > 0.05). There is no significant relationship between ORR and cycles of treatment (P > 0.05), but DCR was significantly related with cycles of treatment (P < 0.05). No clinically significant side effects were observed. There were no significant changes of T cell subsets including CD3⁺, CD4⁺, CD8⁺, CD4⁺ CD25⁺ Treg cells except Th1 in peripheral blood between day 30 after immunotherapy and 1 day before immunotherapy in 11 patients.

Conclusion

DC-CIK is feasible and effective in treating advanced renal cancer and thus provides a new approach.

Trial registration

ClinicalTrials.gov Identifier: NCT01924156. Registration date: August 14, 2013.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
• [2]Koul H, Huh JS, Rove KO, Crompton L, Koul S, Meacham RB, Kim FJ: Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res 2011, 1:240-254.
• [3]Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
• [4]Escudier B: Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012, 8:35-40.
• [5]Palucka K, Banchereau J, Mellman I: Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33:464-478.
• [6]Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999, 81:1009-1016.
• [7]Thanendrarajan S1, Nowak M, Abken H, Schmidt-Wolf IG: Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res 2011, 35:1136-1142.
• [8]Sun Y, Chen J, Cai P, Hu YH, Zhong GC, Feng HZ: Therapy of relapsed or refractory non-Hodgkin’s lymphoma by antigen specific dendric cells-activated lymphocytes. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18:219-223.
• [9]Yagoda A, Bander NH: Failure of cytotoxic chemotherapy,1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 1989, 44:338-345.
• [10]Hirschowitz E, Foody T, Hidalgo G, Yannelli J: Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007, 57:365-372.
• [11]Yang B, Lu XC, Zhu HL, Han WD, Wang Y, Fan H, Li SX, Liu Y, Dai HR, Yao SQ: Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18:1244-1249.
• [12]Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD: Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with ALdesleukin (Interleukin2) and IFN-α2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 2009, 15:4986-4992.
• [13]Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 8:1928-1935.
• [14]Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mappingthe way. Nat Med 2004, 10:475-480.
• [15]Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M, Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN): Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004, 22:1188-1194.
• [16]Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunothérapie. N Engl J Med 1998, 338:1272-1278.
• [17]Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ: Activity of single-agent Bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Clin Genitourin Cancer 2013, 11:45-50.
• [18]Bukowski RM, Eisen T, Szczylik C: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 2007, 25:abstract5023.
• [19]Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
• [20]Maroto JP, Del Muro XG, Mellado B, Perez-Gracia JL, Andrés R, Cruz J, Gallardo E, Domenech M, Arranz JA, Meana JA: Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC). Clin Transl Oncol 2013. [Epub ahead of print]
• [21]Lesterhuis WJ1, Haanen JB, Punt CJ: Cancer immunotherapy--revisited. Nat Rev Drug Discov 2011, 10:591-600.
• [22]Weber J: Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother Nat Rev Drug Discov 2011, 10:591-600.
• [23]Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J: Improved endpoints for cancer immunotherapy trials. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010, 18:1388-1397.
• [24]Knutson KL1, Disis ML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005, 54:721-728.
• [25]Kraemer M, Hauser S, Schmidt-Wolf IG: Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. Anticancer Res 2010, 30:2081-2086.